Article
Difficulties of gender affirming treatment in trans women with BRCA1+ mutation: A case report.
Endocrinologia, diabetes y nutricion - 1 Mar 2024
Piñar-Gutiérrez Ana, Dueñas Disotuar Suset, de Lara-Rodríguez Irene, Amuedo-Domínguez Sandra, González-Cejudo Carmen, Tejero-Delgado José, Mangas-Cruz Miguel Ángel
Abstract excerpt
Gender affirming treatment in transgender women is based on a combination of antiandrogens and estrogens, with the latter maintained over the long term. When prescribing these treatments, we must consider the possibility of developing estrogen-dependent breast cancer. In transgender women, a breast cancer incidence of 4.1 per 100,000 has been estimated, which would increase the risk by 46% in relation to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.